MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer.

Prostate cancer is a highly prevalent disease in older men of the western world. MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression via posttranscriptional inhibition of protein synthesis. To identify the diagnostic potential of miRNAs in prostate cancer, we downloaded the miRNA expression profile of prostate cancer from the GEO database and analysed the differentially expressed miRNAs (DE-miRNAs) in prostate cancerous tissue compared to non-cancerous tissue. Then, the targets of these DE-miRNAs were extracted from the database and mapped to the STRING and KEGG databases for network construction and pathway enrichment analysis. We identified a total of 16 miRNAs that showed a significant differential expression in cancer samples. A total of 9 target genes corresponding to 3 DE-miRNAs were obtained. After network and pathway enrichment analysis, we finally demonstrated that miR-20 appears to play an important role in the regulation of prostate cancer onset. MiR-20 as single biomarker or in combination could be useful in the diagnosis of prostate cancer. We anticipate our study could provide the groundwork for further experiments.

[1]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[2]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[3]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[4]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[5]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Eklund,et al.  MicroRNA profile analysis of human prostate cancers , 2009, Cancer Gene Therapy.

[7]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[8]  G. Ruvkun,et al.  Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans , 1993, Cell.

[9]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[10]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[11]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[12]  Arif B Ekici,et al.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening , 2012, International journal of cancer.

[13]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[14]  F. Hamdy,et al.  Early diagnosis and surgical management of prostate cancer. , 2004, Cancer treatment reviews.

[15]  Y. Leea,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006 .

[16]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[17]  Chen Xiaochun,et al.  Expression and implication of hypoxia inducible factor-1α in prostate neoplasm , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].

[18]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[19]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[20]  L. Chouchane,et al.  Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. , 2006, Cytokine.

[21]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[22]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[23]  G. Kristiansen,et al.  Suitable reference genes for relative quantification of miRNA expression in prostate cancer , 2010, Experimental & Molecular Medicine.

[24]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[25]  D. Bartel,et al.  Weak Seed-Pairing Stability and High Target-Site Abundance Decrease the Proficiency of lsy-6 and Other miRNAs , 2011, Nature Structural &Molecular Biology.

[26]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[27]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[28]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Marie C. M. Lin,et al.  MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling , 2011, RNA biology.

[30]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[31]  M. J. van der Laan,et al.  Augmentation Procedures for Control of the Generalized Family-Wise Error Rate and Tail Probabilities for the Proportion of False Positives , 2004, Statistical applications in genetics and molecular biology.

[32]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[33]  J. Simons,et al.  Hypoxia-inducible factor-1 in human breast and prostate cancer. , 2006, Endocrine-related cancer.

[34]  C. Shao,et al.  Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. , 2005, Asian journal of andrology.

[35]  Hyeyoung Min,et al.  Got target?: computational methods for microRNA target prediction and their extension , 2010, Experimental & Molecular Medicine.

[36]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[37]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[38]  P. Carroll,et al.  The relative impact and future burden of prostate cancer in the United States. , 2004, The Journal of urology.

[39]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[40]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[41]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[42]  Minoru Kanehisa,et al.  The KEGG database. , 2002, Novartis Foundation symposium.

[43]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[44]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[45]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[46]  G. Semenza,et al.  Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. , 1998, Cancer research.

[47]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[48]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.